Advancing Novel Medical Isotopes for Clinical Trials

archived

The DOE SC program in Isotope R&D and Production (DOE IP) hereby announces its interest in receiving applications for research to facilitate, streamline, and accelerate the translation of novel radioisotopes and their associated chelating agents and linker/ligands, for both diagnosis and treatment, from the laboratory bench to evaluation for potential usage in clinical and pre-clinical trials. Evaluating these materials for use in clinical and pre-clinical trials is beyond the scope of this FOA as well as outside the mission of the DOE IP: Applications requesting support for such evaluations will be declined without merit review. Successful applications would benefit the public by leveraging the scientific and technical capabilities of existing facilities at institutions of higher education, non-profit research institutions, and DOE/National Nuclear Security Administration (NNSA) National Laboratories to accelerate the development process for new diagnostic and therapeutic agents. Applications focused on aspects of isotope R&D not associated with translational research are outside the scope of this FOA and will be declined without merit review. Applications are restricted to recently-developed medical isotopes by the DOE IP (listed on the next page) but are not restricted in chelator/ligand technology. Applications incorporating effective ways to train personnel with essential knowledge and skills related to the production, processing, purification, and distribution of enriched stable and radioactive isotopes are strongly encouraged. While this FOA is administered by the DOE IP, the assessment of submitted proposals will be in coordination with the National Institutes of Health.

High